REG-Syncona Limited: Directorate Change <Origin Href="QuoteRef">SYNCS.L</Origin>

SynconaAnnouncement

16/10/2017 10:40

Syncona Limited

Legal Entity Identifier – 213800X8MBI5VQITLW60

Syncona appoints Robert Hutchinson as Non-Executive Director

16 October 2017

Syncona Ltd, a leading healthcare company focused on investing in and building
global leaders in life science, today announces that Robert Hutchinson has
been appointed as Non-Executive Director of the Company, with effect from 1
November 2017.

Mr Hutchinson brings many years of broad financial experience to the role,
having spent 28 years at KPMG. He was appointed partner in 1999 and
specialised in the audit of banking and fund clients.  He led the firm’s
fund and private equity practices for seven years and served as Head of Audit
for KPMG in the Channel Islands for five years until 2013. 

Mr Hutchinson retired from practice in 2014 and is a Fellow of the Institute
of Chartered Accountants in England and Wales. He served as President of the
Guernsey Society of Chartered and Certified Accountants between 2007 and 2009.

There is no information to be disclosed pursuant to LR 9.6.13R in respect of
Mr Hutchinson.  As at the date of this announcement, he has no beneficial
interests in the ordinary shares of the Company.

 ENDS 

Enquiries

Syncona Ltd
Siobhan Weaver
Tel: +44 (0) 20 7611 2031

Tulchan Communications
Martin Robinson
Lisa Jarrett-Kerr
Tel: +44 (0) 207 353 4200

Notes to Editors

About Syncona:

Syncona is a leading FTSE250 healthcare company focused on investing in and
building global leaders in life science. Our vision is to deliver
transformational treatments to patients in truly innovative areas of
healthcare while generating superior returns for shareholders. Our current
investment portfolio consists of seven high quality companies in life science
and a leading range of fund investments.

We seek to partner with the best, brightest and most ambitious minds in
science to build globally competitive businesses. We are established leaders
in gene therapy, cell therapy and advanced diagnostics, and focus on
delivering dramatic efficacy for patients in areas of high unmet need.

Our market leading funds portfolio seeks to generate superior returns by
investing in long only and alternative investment funds. This represents a
productively deployed evergreen funding base which enables us to take a long
term approach to investing in life sciences as we target the best new
opportunities and support our existing portfolio companies to grow and
succeed.

Syncona is aligned with two of the premium charitable funders in UK science,
the Wellcome Trust, original founder of Syncona, and Cancer Research UK, both
of which are significant shareholders in our business.  We make a donation of
0.3% of Net Asset Value to a range of charities each year.



Copyright (c) 2017 PR Newswire Association,LLC. All Rights Reserved